Edgar Filing: GONELLA JACQUES - Form 4

GONELLA JA	CQUES									
Form 4										
May 24, 2013	_									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE CON Washington, D.C. 20549					COMMISSION	ОМВ	Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response0.5			
Check this b if no longer subject to Section 16. Form 4 or Form 5 obligations may continu <i>See</i> Instructi 1(b).	Filed purs section 17(a)	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940								
(Print or Type Res	sponses)									
			2. Issuer Name and Ticker or Trading Symbol ANTARES PHARMA, INC. [ATRS]				5. Relationship of Reporting Person(s) to Issuer(Check all applicable)			
(Last) C/O ANTARE INC., 100 PRI SUITE 300		(Month 05/22	of Earliest Tr //Day/Year) /2013	ansaction			X Director Officer (give below)	X 109		
	nendment, Da Ionth/Day/Year					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
EWING, NJ 0	8628						Form filed by N Person	More than One Re	eporting	
(City)	(State) (Z	Zip) Ta	ble I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned	
	2. Transaction Date Month/Day/Year)		3. if Transactio Code	4. Securiti on(A) or Dis (D) (Instr. 3, 4	ies Ac sposed	quired l of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-	
Common Stock	05/22/2013		A	27,778 (1)	A	<u>(2)</u>	8,946,913	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Reporting Owners

Edgar Filing: GONELLA JACQUES - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
GONELLA JACQUES C/O ANTARES PHARMA, INC. 100 PRINCETON SOUTH, SUITE 300 EWING, NJ 08628	Х	Х					
Signatures							
Robert F. Apple as attorney-in-fact for Ja Gonella	05/24/2013						
<u>**</u> Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents grant of shares of restricted common stock, par value of \$0.01 per share, issued under Antares Pharma, Inc. 2008 Equity (1) Compensation Plan in lieu of Director's annual grant of options. The shares vest after one year.
- (2) Not applicable

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.